Pamela S. Becker, MD, PhD, discusses the rationale for investigating uproleselan in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.
Pamela S. Becker, MD, PhD
Advertisement
Articles by Pamela S. Becker, MD, PhD
Although many patients with cancer now receive chemotherapy as outpatients, most cancer treatment centers do not extend this practice to patients with acute myeloid leukemia (AML) or advanced myelodysplastic syndromes (MDS) who are receiving initial intensive induction therapy.
Advertisement
Latest Updated Articles
Dr. Becker on the Rationale for Investigating Uproleselan in Combination with Chemotherapy in AMLPublished: March 24th 2022 | Updated:
New Model for Outpatient Induction Chemotherapy for AML and MDS ExploredPublished: May 28th 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5